MetaCap

Arbutus Biopharma Insider Trades

NASDAQ: ABUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.08-0.215 (-5.01%)

Market open · Delayed 15 min · as of Oct 8, 10:57 AM ET

Last 12 months

Purchases
0 · $0
Sales
0 · $0
Shares bought / sold
0 / 0
Net activity
Net buying $0

Arbutus Biopharma insider activity

Over the last 12 months, Arbutus Biopharma insiders reported 15 transactions on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Roivant Sciences Ltd. (Director) reporting a transaction in 8,967,383 shares at $5.00 on Oct 1, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put ABUS's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

ABUS insider transactions

Arbutus Biopharma insider transactions
DateInsiderTypeSharesValueFiling
Oct 1, 2026Roivant Sciences Ltd.DirectorDisposition8,967,383$44.84MForm 4
Sep 18, 2026Beardsley Robert ADirectorTax withholding99,057$502.22KForm 4
Sep 18, 2026Beardsley Robert ADirectorOption exercise78,800$334.11KForm 4
Sep 18, 2026Beardsley Robert ADirectorOption exercise52,533$168.11KForm 4
Sep 18, 2026Sawhney RogerDirectorTax withholding100,508$509.58KForm 4
Sep 18, 2026Sawhney RogerDirectorOption exercise78,800$334.11KForm 4
Sep 18, 2026Sawhney RogerDirectorOption exercise52,533$175.46KForm 4
Sep 18, 2026Nguyen TuanChief Financial OfficerTax withholding206,637$1.05MForm 4
Sep 18, 2026Nguyen TuanChief Financial OfficerOption exercise27,475$120.62KForm 4
Sep 18, 2026Nguyen TuanChief Financial OfficerOption exercise265,625$927.03KForm 4
Sep 18, 2026Androski LindsayPresident and CEOTax withholding82,527$418.41KForm 4
Sep 18, 2026Androski LindsayPresident and CEOOption exercise10,456$45.90KForm 4
Sep 18, 2026Androski LindsayPresident and CEOOption exercise116,408$372.51KForm 4
Feb 2, 2026Nguyen TuanChief Financial OfficerAward73,500—Form 4
Feb 2, 2026Androski LindsayPresident and CEOAward28,000—Form 4
Feb 14, 2025Sims KarenChief Medical OfficerAward49,300—Form 4
Feb 14, 2025HASTINGS DAVID CChief Financial OfficerAward90,100—Form 4
Feb 14, 2025McElhaugh Michael J.Interim President & CEOAward177,000—Form 4
Feb 14, 2025Naftzger J. ChristopherGeneral Counsel and CCOAward54,300—Form 4
Feb 4, 2025Naftzger J. ChristopherGeneral Counsel and CCOSale11,333$37.21KForm 4
Feb 4, 2025McElhaugh Michael J.Interim President & CEOSale23,790$78.10KForm 4
Feb 4, 2025HASTINGS DAVID CChief Financial OfficerSale22,183$72.83KForm 4
Feb 4, 2025Sims KarenChief Medical OfficerSale19,348$63.52KForm 4
Aug 14, 2024MANCHESTER KEITH SDirectorSale8,846$32.64KForm 4
Aug 14, 2024MANCHESTER KEITH SDirectorOption exercise54,915$30.75KForm 4
Feb 2, 2024McElhaugh Michael J.Interim President & CEOSale10,164$23.50KForm 4
Feb 2, 2024HASTINGS DAVID CChief Financial OfficerSale9,593$22.18KForm 4
Feb 2, 2024Sims KarenChief Medical OfficerSale4,358$10.08KForm 4
Feb 2, 2024Sofia Michael J.Chief Scientific OfficerSale9,982$23.08KForm 4
Feb 1, 2024McElhaugh Michael J.Interim President & CEOAward123,800—Form 4
Feb 1, 2024HASTINGS DAVID CChief Financial OfficerAward112,500—Form 4
Feb 1, 2024Sims KarenChief Medical OfficerAward101,000—Form 4
Feb 1, 2024Naftzger J. ChristopherGeneral Counsel and CCOAward95,100—Form 4
Feb 1, 2024Sofia Michael J.Chief Scientific OfficerAward109,500—Form 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related